Implementing Controls Around Grants, Consulting Agreements, CME, Preceptorships, and Other Promotional Practices Paul E. Kalb Heidi C. Chen Fourth Annual.

Slides:

Advertisements

Similar presentations

4.02 Compliance Training Brian A. Dahl Senior Counsel Takeda Pharmaceuticals North America, Inc. November 14, 2003.

Advertisements

Key responsibilities of the Board Global Corporate Governance Forum Corporate Governance Leadership Program July 9-15, 2006 Chris Pierce Global Corporate.

Pharmaceutical Compliance Current Trends: Hot Button Issues to Look at this Year in Sales, Marketing, Clinical, Medical Affairs and Government Pricing.

Office of Inspector General (OIG) Internal Audit

Section 1 Guidelines for Office of Inspector General Quality Control and Assurance Programs Peer Review Training – National Science Foundation August 16,

Internal Auditing and Outsourcing

Clinical Compliance Programs: Investigator Payments, GCPs, and More…. Teri Crouse, J.D. Director of Compliance for Healthcare & Marketing.

The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress Compliance Best Practices in a Post Orthopedic Environment David Matyas.

# Operating Under the New Compliance Environment: Considerations for the Pharmaceutical Industry The Impact of the new Medicare Prescription Drug benefit.

© 2009 The McGraw-Hill Companies, Inc. All rights reserved. 1 McGraw-Hill Chapter 5 HIPAA Enforcement HIPAA for Allied Health Careers.

Voluntary Codes MassMEDIC Meeting Are You Ready to Comply with Massachusetts’ New Pharmaceutical and Medical Device Code of Conduct Law? Linda D. Bentley,

CORPORATE COMPLIANCE Tim Timmons Vice President Compliance and Regulatory Services Health Future, LLC.

OIG COMPLIANCE GUIDANCE FOR PHYSICIAN PRACTICES Washington County Hospital Association, Inc. CME Program October 26, 2000.

Copyright 2011 Fennemore Craig, P.C. 1 STANDARDS OF CONDUCT FOR NONPROFIT LEADERS Laura A. Lo Bianco Fennemore Craig, P.C. May 17, 2011.

Developing and Implementing an Effective Compliance Program Mary Sacilotto,BA,CHC Chief Compliance Officer Alliance, Inc.

Developing an Effective Ethics Program

Pitfalls and Lessons Learned: Advanced Implementation Strategies for a Compliant Grant Process National CME Audioconference December 9, 2008.

Corporate Responsibility and Compliance A Resource for Health Care Boards of Directors By Debbie Troklus, CHC and Michael C. Hemsley, Esq.

1 Strategies for a Compliant Grant Process CIA Monitoring Obligations A. Monica Jonhart Director-U S Pharmaceuticals Compliance Bristol-Myers Squibb.

ALEX STEWART INTERNATIONAL’S CODE OF PROFESSIONAL CONDUCT.

Practice Management Quality Control

The Ninth Annual Pharmaceutical Regulatory Compliance Congress and Best Practices Forum Thomas E. Costa Bristol-Myers Squibb Company This presentation.

Pharmaceutical Regulatory and Compliance Congress Special Pre-Conference Workshop: HHS OIG Model Compliance Guidance November 13, 2002.

Managing the Money Trail in the Research Environment Seth B. Whitelaw Compliance Officer, Global R&D GlaxoSmithKline 14 November 2002.

1 Continuing Medical Education and Industry Sponsorship The Pharma, Biotech and Device Colloquium Princeton, NJ June 7, 2005 Julie K. Taitsman, M.D., J.D.

1 Harvard University Cambridge, MA March 29, 2007 Medical Device Congress AdvaMed’s Efforts to Promote Compliance Christopher L. White, Esq. Executive.

How to Operationalize the Guidance In A Pharmaceutical Company OIG Guidance Pharma Audioconference Doug Lankler May 21, 2003.

Kingsley Karunaratne, Department of Accounting, University of Sri Jayewardenepura Colombo – Sri Lanka, Practice Management Quality.

Building A Pharmaceutical Compliance Program Presentation to the Sixth Annual Congress on Health Care Compliance February 7, 2003 Janice Toran Fujisawa.

Compliance Issues in Dealing With Drug and Device Manufacturers Presentation to The Sixth Annual National Congress On Health Care Compliance Paul E. Kalb,

An Overview THE AUDIT PROCESS. MAJOR PHASES IN AN AUDIT Client acceptance and retention Establish terms of the engagement Plan the audit Consider internal.

1 Compliance vs. the Law Department: How to Work Together Michael Dusseau Senior Director, Compliance North America Schering-Plough David Ralston, Esq.

0 Due Diligence Monitoring and Auditing of Third Party Vendors October 28, 2008 Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum.

Governance, Risk and Ethics. 2 Section A: Governance and responsibility Section B: Internal control and review Section C: Identifying and assessing risk.

Chapter 5 ASX Guidelines for Listed Companies

CONFLICTS AND CONFIDENTIALITY

PwC Keys to Negotiating a Corporate Integrity Agreement

Well Trained International

Auditing & Investigations I

Developing an Effective Ethics Program

Audit Planning, Types of Audit Tests and Materiality

Action Items: Monitoring Off-Label Promotion Do’s and Don’t’s

How to Apply for and Receive Industry Funding for Investigator Sponsored Research Chuck Simonton MD, FACC, FSCAI Chief Medical Officer Abbott Vascular.

Internal and Governmental Financial Auditing and Operational Auditing

Implementing 2 CFR 200 Carrie Kronberg Housing Programs Manager

Safety Accountabilities

Построение культуры integrity в компании Aнар Каримов партнёр «ЭКВИТА»

Analysis of the Proposed Sunshine Rule: Legal Considerations

2005 Deficit Reduction Act: Fraud, Waste & Abuse, and Compliance Training 9/21/2018.

Compliance Program 2018.

VIth AIDA EUROPE CONFERENCE (Vienna, 3-4 November 2016)

Training Objectives What is the Signature Partners MSSP ACO?

The Role of Internal Audit in Health Care Compliance

The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress Beyond the DOJ: Compliance Best Practices in the Orthopedic Environment.

Public Health Interventions

Chapter 8 Developing an Effective Ethics Program

Risk Management: why and how to protect your health center

Brussels, June 6, 2007 Paul E. Kalb, M.D., J.D.

The Elements of appropriate Internal Controls

ACCOUNTING ETHICS Conf.univ.dr. Victor-Octavian Müller.

California’s “Comprehensive Compliance Program” Law

“Netting” Prices Pharmaceutical Compliance Congress November 15, 2004

ACCOUNTING ETHICS Conf.univ.dr. Victor-Octavian Müller.

Taking the STANDARDS Seriously

Managing Privacy Risk in Your Commercial Practices

Pharmaceutical Congress: Responding to the Guidance

ACCOUNTING ETHICS Conf.univ.dr. Victor-Octavian Müller.

ACCOUNTING ETHICS Conf.univ.dr. Victor-Octavian Müller.

ACCOUNTING ETHICS Lect. Victor-Octavian Müller, Ph.D.

Good practices for risk assessment and control activities

Presentation transcript:

Implementing Controls Around Grants, Consulting Agreements, CME, Preceptorships, and Other Promotional Practices Paul E. Kalb Heidi C. Chen Fourth Annual Pharmaceutical Regulatory and Compliance Congress November 13, 2003

The Challenge: How can a manufacturer purchase goods or services from, or make a grant to, a customer without violating the Anti-Kickback statute or the Medicaid Rebate statute?

The Answer: Bona Fide From Latin: In Good Faith Payments must be good, and company must have faith that its employees are acting appropriately.

What makes payments “good”: The Top 10 Considerations 1. Is the proposed arrangement a true “consulting” arrangement? 2. Is there a written agreement between the company and the consultant specifying the nature of the services to be performed and the basis for payment? 3. Does the consulting relationship have a commercially reasonable business purpose that has been identified in advance? 4. Have the consultants been chosen based on their expertise and skills? 5. Who is responsible for selecting the consultants?

What makes payments “good”: The Top 10 Considerations 6. Is the number of consultants to be used reasonable in light of the scope of the task and the importance of the services? 7. Will the information generated by the consultants be used? 8. Is the remuneration to be offered at fair market value, without taking into account the number or value of referrals or other business generated? 9. Will any meeting be held at an appropriate venue and under appropriate circumstances? 10. Will the consultants be engaged in “white coat marketing”?

Special Issues in Managed Care Concern Over Influencing Formulary Decisions OIG Warning re: Dual Benefit/Dual Purpose

Special Considerations re: Government Employees VA, DoD 20/50 Rule Appearance of Conflict

Procedural Safeguards: Controlling a Large Organization “Trust, but verify.” -Ronald Reagan

OIG Compliance Program Guidance 1. Code of Conduct, policies and procedures 2. Compliance officer and committee 3. Regular, effective training 4. Effective lines of communication 5. Monitoring 6. Discipline and non-retention of excluded individuals 7. Investigation and reporting instances of non-compliance

The Key: Verify Faith is important, but so is verification Need to look, listen, and ask hard questions

Lessons from CIAs Bring in a fresh pair of eyes Focus on areas of greatest risk Be systematic and regular Evaluate, correct, and report (as necessary)

Paul E. Kalb Heidi C. Chen November 13, 2003